Abstract
Human recombinant tissue type plasminogen activator (rt-PA) first became available in Europe for medium-scale clinical trials in acute myocardial infarction early in 1984, provided by Boehringer Ingelheim GmbH in collaboration with Genentech Inc. A small steering committee was set up under the chairmanship of Professor M. Verstraete to plan and coordinate these trials — the members of this committee, and of the others who participated in the studies, are listed at the end of this paper. On the basis of experience with previous thrombolysis trials using other agents (1, 5) and of pilot studies with rt-PA in Europe and the United States of America (2, 4), it was decided that the first priority was to establish whether rt-PA was going to be an effective, rapid and safe thrombolytic agent when given by the intravenous route.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Been M, de Bono DP, Muir AL, Boulton FE, Hillis WS, Hornung R (1985) Coronary thrombolysis with intravenous anisoylated plasminogen streptokinase complex. Br Heart J 53:253–259
Collen D, Topol EJ, Tiefenbrunn AJ et al (1984) Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo controlled trial. Circulation 70:1012–1017
The TIMI study group (1985) The thrombolysis in myocardial infarction (TIMI) trial. Phase 1 findings. New Engl J Med 312:932–936
van der Werf F, Ludbrook PA, Bergmann SR et al (1984) Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. New Engl J Med 310:609–613
Verstraete M, van der Loo J, Jesdinsky HJ (1980) Streptokinase in myocardial infarction — extended report of the European cooperative trial. Acta Med Scand 68 (Suppl):l-55
Verstraete M, Bernard R, Bory M et al (1985) Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European cooperative study group. Lancet i:842–847
Verstraete M, Bleifeld W, Brower RW et al (1985) Double blind randomised trial of intravenous tissue type plasminogen activator versus placebo in acute myocardial infarction. Lancet ii:965–969
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
de Bono, D.P. (1986). Clinical experience with rt-PA in the Cooperative European Trials 1. rt-PA versus placebo. In: Effert, S., von Essen, R., Hugenholtz, P.G., Uebis, R., Verstraete, M. (eds) Facts and Hopes in Thrombolysis in Acute Myocardial Infarction. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-662-07174-8_22
Download citation
DOI: https://doi.org/10.1007/978-3-662-07174-8_22
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-662-07176-2
Online ISBN: 978-3-662-07174-8
eBook Packages: Springer Book Archive